- Home
- GDS vs MIRM Comparison
GDS vs MIRM Comparison
Compare GDS & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GDS | MIRM |
|---|---|---|
| Founded | 2001 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 7.2B |
| IPO Year | 2016 | 2019 |
Fundamental Metrics
Financial Performance| Metric | GDS | MIRM |
|---|---|---|
| Price | $31.21 | $101.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 13 |
| Target Price | $45.27 | ★ $119.85 |
| AVG Volume (30 Days) | ★ 1.6M | 598.0K |
| Earning Date | 05-19-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 74.59 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $19,138,000.00 |
| Revenue This Year | $12.93 | $26.22 |
| Revenue Next Year | $13.27 | $22.04 |
| P/E Ratio | $52.69 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.97 | $63.23 |
| 52 Week High | $48.61 | $130.00 |
Technical Indicators
Market Signals| Indicator | GDS | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 42.44 | 47.86 |
| Support Level | $30.79 | $88.08 |
| Resistance Level | $34.06 | $105.20 |
| Average True Range (ATR) | 1.21 | 3.23 |
| MACD | -0.28 | 0.71 |
| Stochastic Oscillator | 14.43 | 58.39 |
Price Performance
Historical ComparisonAbout GDS GDS Holdings Limited ADS
GDS Holdings started as an IT service provider in 2001, then moved to the data center business with its first self-developed data center opening in 2010. The company now develops and operates data centers in China and also builds, operates, and transfers data centers for other clients. It offers colocation and managed services and mainly targets hyperscale cloud service customers who take large areas of its data centers or even whole data centers under long-term contracts. Its data centers are located predominantly in and around the Tier 1 cities in China, and it has also started expanding into Southeast Asia via the now 23% owned DayOne. GDS listed on the Nasdaq in 2016 and completed a secondary listing in Hong Kong in 2020.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.